New clinical data highlights circular RNAs (circRNAs) as a novel, non-invasive blood biomarker platform for the early detection of Alzheimer’s Disease (AD). The research demonstrates that circRNAs offer comprehensive insights into the multiple disrupted disease pathways central to AD’s biology and pathology.
SAN DIEGO, Nov. 24, 2025 /PRNewswire/ — Circular Genomics, Inc., a leading neurological and psychiatric precision medicine company, today announced that new findings from its Alzheimer’s disease (AD) program will be presented at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference on December 3, 2025, in San Diego, CA. The data will highlight the company’s proprietary circRNA biomarker platform and its ability to identify AD patients early in the disease process ultimately leading to more timely interventions.
Read the full article on prnewswire.com
Share this page on social